secwatch.observer — SEC 8-K summary
======================================

Issuer:     NewAmsterdam Pharma Co N.V. (NAMS)
CIK:        0001936258
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001193125-26-210283
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NewAmsterdam Pharma reports Q1 net loss of $48.4M; PREVAIL interim analysis planned for 4Q26
--------------------------------------------------------------------------------

- Net loss $48.4M for Q1 2026, compared to net loss $39.5M in Q1 2025.
- Cash and marketable securities $707.3M at March 31, down from $728.9M at Dec 31, 2025.
- Regulatory decisions on obicetrapib from EMA, UK, Switzerland expected in 2H26; potential launches by Menarini in 4Q26 in Germany and UK.
- PREVAIL CVOT interim analysis planned for 4Q2026, result expected 1Q2027; trial may stop for efficacy or complete by end of 2027.
- Completed enrollment in REMBRANDT Phase 3 (323 patients); RUBENS Phase 3 topline data expected by year-end 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1936258/000119312526210283/0001193125-26-210283-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1936258/000119312526210283/nams-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-210283

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer